Outcomes and cost-effectiveness of different models of delivery of antiretroviral therapy

 

Show simple item record

dc.contributor.advisor Maartens, Gary
dc.contributor.advisor Cleary, Susan
dc.contributor.author Leisegang, Rory
dc.date.accessioned 2018-09-04T13:32:16Z
dc.date.available 2018-09-04T13:32:16Z
dc.date.issued 2018
dc.identifier.citation Leisegang, R. 2018. Outcomes and cost-effectiveness of different models of delivery of antiretroviral therapy. University of Cape Town. en_ZA
dc.identifier.uri http://hdl.handle.net/11427/28386
dc.description.abstract Background: HIV remains a major contributor to the burden of disease in the Eastern and Southern African region, where around half of those with HIV/AIDS reside, according to the 2016 UNAIDS estimates. Data on the direct costs and outcomes of providing health care are important due to competing health needs and limited budgets in resource-limited settings, especially if we are to reach the UNAIDS 90-90-90 goals. This thesis presents a series of studies, which together represent the typical journey followed within an economic evaluation, starting with the establishment of a cohort, then onto cost and outcome analyses and, finally, the development of a Markov model for the purpose of establishing the cost-effectiveness of a particular intervention. Methods: Data for this thesis come from several cohorts within South Africa, with patients commencing ART between 1998 and 2014, and with care provided within a number of different models: private (Aid for AIDS), public-private partnerships or PPP (BroadReach), and public sector (Khayelitsha). The study design for all were retrospective cohort analyses. These cohorts had important strengths in their data: adherence measures (private, PPP); initiating ART at CD4 counts > 200 cells/µL (private); detailed cost data (private); long duration of follow-up with a larger proportion on second-line ART (private); ability to assess health care utilization pre-ART and in patient loss to ART follow-up (private); and availability of national identity numbers, allowing us to confirm mortality from national death register data (private, PPP). Results: The results sections of this thesis are presented in the form of published papers and chapters. In the first analysis (Chapter 4), we present a cohort profile for Aid for AIDS, where we describe the history of the programme and contrast it with the public sector programme in South Africa. In the second analysis (Chapter 5), we present a paper highlighting the profile and determinants of costs on ART over time in the private cohort. We draw attention to the impact of baseline stage and adherence to ART on early and late costs respectively. In the third analysis (Chapter 6), we explore different models of HIV care: GP versus clinic for public sector patients and courier versus collect pharmacy for private sector patients. In the third analysis (Chapter 7), we present a paper which reviews cost-effectiveness studies in LMICs and explores the relative impact of various factors on costs and mortality in preparation for the final analysis (Chapter 8), which required the development of a novel HIV Markov model. Conclusion: Interventions, such as public-private partnerships with GPs or home-refill by courier, which we have found to be associated with lower costs and improved outcomes respectively, should be considered for implementation in South Africa, especially in light of the proposed National Health Insurance. The focus of this thesis on models of ART delivery and the inclusion of under-represented or novel models are significant strengths.
dc.language.iso eng
dc.subject.other Clinical Pharmacology
dc.title Outcomes and cost-effectiveness of different models of delivery of antiretroviral therapy
dc.type Doctoral Thesis
dc.date.updated 2018-09-03T06:28:34Z
dc.publisher.institution University of Cape Town
dc.publisher.faculty Faculty of Health Sciences en_ZA
dc.publisher.department Department of Medicine en_ZA
dc.type.qualificationlevel Doctoral
dc.type.qualificationname PhD
uct.type.filetype Text
uct.type.filetype Image
dc.identifier.apacitation Leisegang, R. (2018). <i>Outcomes and cost-effectiveness of different models of delivery of antiretroviral therapy</i>. (). University of Cape Town ,Faculty of Health Sciences ,Department of Medicine. Retrieved from http://hdl.handle.net/11427/28386 en_ZA
dc.identifier.chicagocitation Leisegang, Rory. <i>"Outcomes and cost-effectiveness of different models of delivery of antiretroviral therapy."</i> ., University of Cape Town ,Faculty of Health Sciences ,Department of Medicine, 2018. http://hdl.handle.net/11427/28386 en_ZA
dc.identifier.vancouvercitation Leisegang R. Outcomes and cost-effectiveness of different models of delivery of antiretroviral therapy. []. University of Cape Town ,Faculty of Health Sciences ,Department of Medicine, 2018 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/28386 en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Leisegang, Rory AB - Background: HIV remains a major contributor to the burden of disease in the Eastern and Southern African region, where around half of those with HIV/AIDS reside, according to the 2016 UNAIDS estimates. Data on the direct costs and outcomes of providing health care are important due to competing health needs and limited budgets in resource-limited settings, especially if we are to reach the UNAIDS 90-90-90 goals. This thesis presents a series of studies, which together represent the typical journey followed within an economic evaluation, starting with the establishment of a cohort, then onto cost and outcome analyses and, finally, the development of a Markov model for the purpose of establishing the cost-effectiveness of a particular intervention. Methods: Data for this thesis come from several cohorts within South Africa, with patients commencing ART between 1998 and 2014, and with care provided within a number of different models: private (Aid for AIDS), public-private partnerships or PPP (BroadReach), and public sector (Khayelitsha). The study design for all were retrospective cohort analyses. These cohorts had important strengths in their data: adherence measures (private, PPP); initiating ART at CD4 counts > 200 cells/µL (private); detailed cost data (private); long duration of follow-up with a larger proportion on second-line ART (private); ability to assess health care utilization pre-ART and in patient loss to ART follow-up (private); and availability of national identity numbers, allowing us to confirm mortality from national death register data (private, PPP). Results: The results sections of this thesis are presented in the form of published papers and chapters. In the first analysis (Chapter 4), we present a cohort profile for Aid for AIDS, where we describe the history of the programme and contrast it with the public sector programme in South Africa. In the second analysis (Chapter 5), we present a paper highlighting the profile and determinants of costs on ART over time in the private cohort. We draw attention to the impact of baseline stage and adherence to ART on early and late costs respectively. In the third analysis (Chapter 6), we explore different models of HIV care: GP versus clinic for public sector patients and courier versus collect pharmacy for private sector patients. In the third analysis (Chapter 7), we present a paper which reviews cost-effectiveness studies in LMICs and explores the relative impact of various factors on costs and mortality in preparation for the final analysis (Chapter 8), which required the development of a novel HIV Markov model. Conclusion: Interventions, such as public-private partnerships with GPs or home-refill by courier, which we have found to be associated with lower costs and improved outcomes respectively, should be considered for implementation in South Africa, especially in light of the proposed National Health Insurance. The focus of this thesis on models of ART delivery and the inclusion of under-represented or novel models are significant strengths. DA - 2018 DB - OpenUCT DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 2018 T1 - Outcomes and cost-effectiveness of different models of delivery of antiretroviral therapy TI - Outcomes and cost-effectiveness of different models of delivery of antiretroviral therapy UR - http://hdl.handle.net/11427/28386 ER - en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record